MarketPulse

azetukalner

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Xenon Pharmaceuticals Inc.

Xenon's Seizure Drug Azetukalner Shows Strong Phase 3 Results Ahead of 2026 FDA Filing

Xenon Pharmaceuticals reports positive Phase 3 data for azetukalner in focal onset seizures, with 53.2% seizure reduction versus 10.4% placebo. FDA submission planned for Q3 2026.
XENEPhase 3 clinical trialFDA approval
The Motley FoolThe Motley Fool··Jonathan Ponciano

Xenon Pharma Soars 55% on Trial Success Despite Insider Share Sale

Xenon Pharmaceuticals' CMO sold $78K in shares via routine vesting, as stock surges 55% following positive Phase 3 trial results and $750M capital raise.
XENEbiotechcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Xenon Pharma Raises $650M in Upsized Offering to Fund Pipeline Growth

Xenon Pharmaceuticals prices $650M upsized offering at $57/share with 10.5M shares. Proceeds fund pipeline acceleration; closes March 2026.
XENEpublic offeringcapital raise